Peptides / Weight and metabolic

Synthetic analog · 37 amino acids · 4,409.1 Da

Cagrilintide

Not approvedBanned in sport

Cagrilintide is an experimental form of the hormone amylin, tested alone and with semaglutide as CagriSema in phase 3 trials, and not approved. Studies in people tested it for weight loss and blood sugar, and tracked stomach side effects. PepBank shows 75 results on cagrilintide from 14 studies in people, and 55 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as AM833, NNC0174-0833

Cagrilintide is also in CagriSema, a fixed combination with semaglutide.

37 amino acids, from first to last3 changed amino acids

Evidence level: Large trials in people75 of 130 results come from studies in people, including randomized trials.

Results in people

58% of 130 results

Results in animals

33% of 130 results

Results in lab cells

9% of 130 results

From computer models

0% of 130 results

Overview

Cagrilintide at a glance

What it is	Synthetic analog, 37 amino acids
Approval	Not approved for any use
In sport	Banned in sport (WADA S0)
Studies	45 studies with results. 26 of them gave cagrilintide, with 130 results. 75 in people43 in animals12 in lab cells
Best study in people	Randomized controlled trial with 331 people (2026)
Clinical trials	53 registered: 18 active or planned, 2 with posted results
Community use	Weight loss, mainly as a part of a "DIY CagriSema" pair with semaglutide

The science

What is cagrilintide?

Investigational lipidated amylin analogue that activates amylin and calcitonin receptors. In phase 3 trials alone and with semaglutide (CagriSema); not approved.

Amino acids in one chain

The history of cagrilintide

2021
The oldest paper on cagrilintide in PepBank is from 2021.
2022November
A registered trial of cagrilintide started (NCT05567796).

Cagrilintide structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 37 amino acidsFrom the first amino acid to the last

+K1CNTA5TCATQ10+RLA−EF15L+RHSS20NNFGP25ILPPT30NVGSN35TP

Darker means more water-repelling+ and − show charge in the bodyOutlined: changed amino acid

Structure

Cagrilintide is a synthetic analog of 37 amino acids, with no ring, 1 disulfide bond, 3 changed amino acids.

Formula

C₁₉₄H₃₁₂N₅₄O₅₉S₂

Molecular weight

4,409.1 g/mol

CAS number

1415456-99-3

Targets

Calcitonin receptor (gene CALCR): agonistEvidence: primary literatureAmylin receptor 1 (CALCR + RAMP1) (gene CALCR/RAMP1): agonistEvidence: primary literatureAmylin receptor 2 (CALCR + RAMP2) (gene CALCR/RAMP2): agonistEvidence: primary literature

Development

Novo Nordisk. Highest phase: phase 3.

Identifiers

PubChem 164618153, ChEMBL CHEMBL4802169, UNII AO43BIF1U8, DrugBank DB18887, IUPHAR 13768, PDB 9BP3

Full sequence, SMILES and InChIKey

Three-letter sequence
HOOC-(CH2)18-CO-gammaGlu-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-NH2 (disulfide Cys2-Cys7)

InChIKey
LDERDVMBIYGIOI-MEMPIPKGSA-N

SMILES
CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N3CCC[C@H]3C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)CNC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CNC=N6)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@@H]8CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N8)[C@@H](C)O)C)[C@@H](C)O)CC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)CC[C@@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O

See charge, composition and 3D structure on the Scientific page

The evidence

What cagrilintide studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Large trials in people75 of 130 results come from studies in people, including randomized trials.

Weight and appetite

56 results · 24 in people · 32 animal

In east Asian adults with overweight or obesity, the combination led to more weight loss than semaglutide alone. The lancet. Diabetes & endocrinology, 2026

Top results

In east Asian adults with overweight or obesity, the combination led to more weight loss than semaglutide alone. (The lancet. Diabetes & endocrinology, 2026)
In mice, cagrilintide lowered food intake in the first days of treatment compared with vehicle. (EBioMedicine, 2025)
In adults with overweight or obesity, every cagrilintide dose led to more weight loss than placebo after 26 weeks. (Lancet, 2021)

Blood sugar

12 results · 9 in people · 3 animal

In adults with type 2 diabetes, HbA1c fell by 0.9 percentage points over 32 weeks of cagrilintide alone. Lancet, 2023

Top results

In adults with type 2 diabetes, HbA1c fell by 0.9 percentage points over 32 weeks of cagrilintide alone. (Lancet, 2023)
In adults with overweight, blood sugar measures improved in every group, including placebo, whatever the cagrilintide dose. (Lancet, 2021)
In adults with overweight or obesity, cagrilintide alone did not significantly change blood sugar measures compared with placebo. (Journal of diabetes and metabolic disorders, 2026)

Heart and blood vessels

4 results · 4 in people

In adults with overweight or obesity, cagrilintide alone modestly improved blood pressure compared with placebo. Journal of diabetes and metabolic disorders, 2026

Top results

In adults with overweight or obesity, cagrilintide alone modestly improved blood pressure compared with placebo. (Journal of diabetes and metabolic disorders, 2026)
In healthy people, cagrilintide did not lengthen the heart QT interval in a relevant way compared with placebo. (Diabetes, obesity & metabolism, 2024)
In adults with overweight or obesity and type 2 diabetes, CagriSema lowered blood pressure about as much as semaglutide did. (Diabetes, metabolic syndrome and obesity, 2026)

Cholesterol and blood fats

2 results · 2 in people

In people with obesity, blood fats were mostly similar with CagriSema and with semaglutide. Diabetes, obesity & metabolism, 2026

Top results

In people with obesity, blood fats were mostly similar with CagriSema and with semaglutide. (Diabetes, obesity & metabolism, 2026)
In people with obesity, LDL cholesterol was slightly higher with CagriSema than with semaglutide. (Diabetes, obesity & metabolism, 2026)

Survival and serious illness

2 results · 2 in people

In adults with type 2 diabetes, no deaths from side effects were reported. Lancet, 2023

Top results

In adults with type 2 diabetes, no deaths from side effects were reported. (Lancet, 2023)
In adults with kidney or liver impairment, no deaths were reported after one cagrilintide dose. (Clinical pharmacokinetics, 2026)

Hormones

1 result · 1 in people

In adults with overweight, hormone changes were similar in the cagrilintide and placebo groups. Lancet, 2021

Top results

In adults with overweight, hormone changes were similar in the cagrilintide and placebo groups. (Lancet, 2021)

All 45 cagrilintide studies by area Open the Scientific page

Key cagrilintide studies

Studies in people come first, then studies in animals and in the lab.

People
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial
Yamauchi et al. 2026 · The lancet. Diabetes & endocrinology · 331 people · cited by 1
4 results
People
Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants
Gabe et al. 2024 · Diabetes, obesity & metabolism · 105 people · cited by 2
1 result
People
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial
Enebo et al. 2021 · Lancet (London, England) · 95 people · cited by 241
12 results
People
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
Frias et al. 2023 · Lancet (London, England) · 30 people · cited by 248
11 results
People
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
Lau et al. 2021 · Lancet (London, England) · cited by 208
8 results

All 45 Cagrilintide studies

Cagrilintide clinical trials

ClinicalTrials.gov lists 53 trials of cagrilintide. 18 are active or planned, and 2 have posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

Phase 3active, not recruiting7,101 planned

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

Phase 3active, not recruiting3,400 planned

A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

Phase 3completed2,734 people

All 12 Cagrilintide trials

Status and safety

Is cagrilintide approved?

FDA

United States

Investigational

Investigational.

EMA

European Union

Not approved

No approved medicine contains it.

WADA

Sport

Banned

On the 2026 Prohibited List, section S0.

No. Not approved for any use. Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 9 Oct 2026). Banned in sport (WADA S0).

Laws and labels change, so check the regulator for the current status.

Cagrilintide side effects and safety

PepBank has 28 safety results from studies of cagrilintide. 28 of them come from studies in people.

Safety results from studies (28)

In healthy people, cagrilintide did not lengthen the heart QT interval in a relevant way compared with placebo. (Diabetes, obesity & metabolism, 2024)
In adults with overweight, nearly everyone had some side effect, with similar rates on cagrilintide and placebo; most were mild or moderate. (Lancet, 2021)
In adults with type 2 diabetes, 80% of people taking cagrilintide alone reported side effects. (Lancet, 2023)
In adults with overweight or obesity, about 1 in 10 stopped treatment for good, at similar rates in all groups, mostly because of side effects. (Lancet, 2021)
In east Asian adults with overweight or obesity, 10% stopped the combination and 6% stopped semaglutide alone. (The lancet. Diabetes & endocrinology, 2026)
In people with obesity, CagriSema caused more stomach and gut side effects than semaglutide alone in this pooled analysis. (Indian journal of endocrinology and metabolism, 2024)
In people with obesity, CagriSema and semaglutide had similar overall rates of side effects. (Diabetes, obesity & metabolism, 2026)
In adults with overweight or obesity, cagrilintide alone caused slightly more side effects than placebo in a pooled analysis. (Annals of medicine and surgery, 2026)
In adults with kidney or liver impairment, side effects after one cagrilintide dose did not increase with more severe impairment. (Clinical pharmacokinetics, 2026)
In adults with type 2 diabetes, mild or moderate stomach and gut side effects were the most common side effects. (Lancet, 2023)
In adults with type 2 diabetes, no serious low blood sugar events were reported. (Lancet, 2023)
In adults with type 2 diabetes, no deaths from side effects were reported. (Lancet, 2023)
In adults with overweight, about 37% of all reported side effects were stomach and gut problems. (Lancet, 2021)
In adults with overweight or obesity, 29 participants (4%) left the trial before the end. (Lancet, 2021)
In adults with overweight or obesity, more people on cagrilintide had stomach and gut side effects than on placebo. (Lancet, 2021)
In adults with overweight or obesity, nausea was more common on cagrilintide than on placebo. (Lancet, 2021)
In adults with overweight or obesity, the most common side effects were stomach and gut problems and reactions where the injection was given. (Lancet, 2021)
In east Asian adults with overweight or obesity, 87% on the combination and 84% on semaglutide alone had side effects. (The lancet. Diabetes & endocrinology, 2026)
In east Asian adults with overweight or obesity, stomach and bowel problems affected 53% on the combination and 51% on semaglutide alone. (The lancet. Diabetes & endocrinology, 2026)
In people with obesity, vomiting was more common with CagriSema than with semaglutide alone in this pooled analysis. (Indian journal of endocrinology and metabolism, 2024)
In people with obesity, vomiting was less common with cagrilintide than with semaglutide or liraglutide in this pooled analysis. (Indian journal of endocrinology and metabolism, 2024)
In people with obesity, CagriSema and semaglutide had similar rates of serious side effects. (Diabetes, obesity & metabolism, 2026)
In people with obesity, CagriSema caused more injection-site problems than semaglutide. (Diabetes, obesity & metabolism, 2026)
In people with obesity, CagriSema caused more nausea than semaglutide. (Diabetes, obesity & metabolism, 2026)

See every safety result on the Scientific page

Doses studied (19 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
cagrilintide 2·4 mg plus semaglutide 2·4 mg once weekly	Human	human	subcutaneous	68 weeks	Randomized trial in people · n = 331	Yamauchi 2026
4.5 mg once weekly (dose escalated)	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 105	Gabe 2024
0.16-4.5 mg	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 95	Enebo 2021
2.4 mg once weekly (escalated)	Human	human	subcutaneous	32 weeks	Randomized trial in people · n = 30	Frias 2023
0.3-4.5 mg	Human	human	subcutaneous	26 weeks	Randomized trial in people	Lau 2021
1.2 mg	Human	human	subcutaneous	20 weeks	Randomized trial in people	Enebo 2021
2.4 mg	Human	human	subcutaneous	20 weeks	Randomized trial in people	Enebo 2021
4.5 mg	Human	human	subcutaneous	20 weeks	Randomized trial in people	Enebo 2021
4.5 mg	Human	human	subcutaneous	26 weeks	Randomized trial in people	Lau 2021
CagriSema 2.4 mg/2.4 mg once weekly	Human	human	Not reported	68 weeks	Randomized trial in people	Busetto 2026
cagrilintide 2.4 mg once weekly	Human	human	Not reported	68 weeks	Randomized trial in people	Busetto 2026
cagrilintide 2.4 mg with semaglutide 2.4 mg	Human	human	Not reported	20-32 weeks	Systematic review of studies	Dutta 2024
2.4 mg	Human	human	Not reported	26-32 weeks	Systematic review of studies	Dutta 2024
0.6 mg	Human	human	subcutaneous	single dose	Trial in people without random groups · n = 33	Nielsen 2026
0.9 mg	Human	human	subcutaneous	single dose	Trial in people without random groups · n = 32	Nielsen 2026
0.6 mg (renal study) or 0.9 mg (hepatic study)	Human	human	subcutaneous	single dose	Trial in people without random groups	Nielsen 2026
3 nmol/kg	Animal	mouse	subcutaneous	3 weeks	Study in live animals · n = 8	Carvas 2025
2 nmol/kg	Animal	rat	subcutaneous	24 or 28 days	Study in live animals	John 2021
10 nmol/kg	Animal	mouse	subcutaneous	24 or 28 days	Study in live animals	John 2021

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

Cagrilintide is an investigational amylin drug. The wiki says community use is very rare. The main reported use is a "DIY CagriSema" pair, with separate cagrilintide and semaglutide products.

Reported routines and cautions

What people use it for

Weight loss, mainly as a part of a "DIY CagriSema" pair with semaglutideS1S2

Reported regimens

Regimens that community sources report for Cagrilintide. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Copying the phase 2 trial doses (reported as niche)	subcutaneous injection	0.3 to 4.5 mg per dose	once weekly	26 to 68 weeks	single source; the source carries seller links	S1
"DIY CagriSema": cagrilintide plus semaglutide from separate products	subcutaneous injectiontwo separate products	2.4 mg per dose	once weekly	ongoing	single source; the source carries seller links	S2

Cautions

Product checks are hard. The wiki says cagrilintide is difficult to make and to verify.S1
A DIY pair of two separate products adds dosing and quality risk. The wiki says it does not replicate the fixed-dose product.S1
The wiki lists no long-term safety data for cagrilintide on its own outside trials.S1

Status notes

FDA says cagrilintide and retatrutide cannot be used in compounding under federal law. They are not components of FDA-approved drugs. FDA page content current as of 2026-10-01.S3
Per a law-firm summary, FDA issued warning letters on 2024-12-17 to five companies that offer GLP-1 products, including cagrilintide. FDA determined that these products are unapproved new drugs.S4

Community sources

S1Cagrilintide: Community Protocols & Reportspeptideprotocolwiki.comcarries seller links, not linked
S2CagriSema: Community Protocols & Reportspeptideprotocolwiki.comcarries seller links, not linked
S3FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (opens in a new tab)fda.gov
S4FDA targets GLP-1 providers with warning letters (opens in a new tab)foley.com

Gaps

Very little community use was found. Both community sources come from one wiki that summarizes Reddit, so they are not independent. Both pages carry seller links. No reported side effects or personal accounts were found. No forum posts with doses were found. Doses listed follow trial doses, not verified user reports.

Questions and more

Ask a question about cagrilintide

The answer links to every study it uses.

What does the evidence say about cagrilintide?Is cagrilintide tested in people?Compare with Liraglutide Compare with Semaglutide

Sources

Database: PepBank data for cagrilintide (data version 308560)
Regulator: WADA status record
Trial registry: ClinicalTrials.gov
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about cagrilintide

Curo is a peptide shop. PepBank and Curo have the same owner. See the Curo catalog (opens in a new tab).

Cagrilintide

Not approvedBanned in sport

Also known as AM833, NNC0174-0833

Cagrilintide is also in CagriSema, a fixed combination with semaglutide.

What it is

Synthetic analog, 37 amino acids

Approval

Not approved for any use

In sport

Banned in sport (WADA S0)

Studies

45 studies with results. 26 of them gave cagrilintide, with 130 results.
75 in people43 in animals12 in lab cells

Best study in people

Randomized controlled trial with 331 people (2026)

Clinical trials

53 registered: 18 active or planned, 2 with posted results

Community use

Weight loss, mainly as a part of a "DIY CagriSema" pair with semaglutide

Dose as reported

Class

Species

Route

Duration

Design

Source

cagrilintide 2·4 mg plus semaglutide 2·4 mg once weekly

Human

human

subcutaneous

68 weeks

Randomized trial in people · n = 331

Yamauchi 2026

4.5 mg once weekly (dose escalated)

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 105

Gabe 2024

0.16-4.5 mg

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 95

Enebo 2021

2.4 mg once weekly (escalated)

Human

human

subcutaneous

32 weeks

Randomized trial in people · n = 30

Frias 2023

0.3-4.5 mg

Human

human

subcutaneous

26 weeks

Randomized trial in people

Lau 2021

1.2 mg

Human

human

subcutaneous

20 weeks

Randomized trial in people

Enebo 2021

2.4 mg

Human

human

subcutaneous

20 weeks

Randomized trial in people

Enebo 2021

4.5 mg

Human

human

subcutaneous

20 weeks

Randomized trial in people

Enebo 2021

4.5 mg

Human

human

subcutaneous

26 weeks

Randomized trial in people

Lau 2021

CagriSema 2.4 mg/2.4 mg once weekly

Human

human

Not reported

68 weeks

Randomized trial in people

Busetto 2026

cagrilintide 2.4 mg once weekly

Human

human

Not reported

68 weeks

Randomized trial in people

Busetto 2026

cagrilintide 2.4 mg with semaglutide 2.4 mg

Human

human

Not reported

20-32 weeks

Systematic review of studies

Dutta 2024

2.4 mg

Human

human

Not reported

26-32 weeks

Systematic review of studies

Dutta 2024

0.6 mg

Human

human

subcutaneous

single dose

Trial in people without random groups · n = 33

Nielsen 2026

0.9 mg

Human

human

subcutaneous

single dose

Trial in people without random groups · n = 32

Nielsen 2026

0.6 mg (renal study) or 0.9 mg (hepatic study)

Human

human

subcutaneous

single dose

Trial in people without random groups

Nielsen 2026

3 nmol/kg

Animal

mouse

subcutaneous

3 weeks

Study in live animals · n = 8

Carvas 2025

2 nmol/kg

Animal

rat

subcutaneous

24 or 28 days

Study in live animals

John 2021

10 nmol/kg

Animal

mouse

subcutaneous

24 or 28 days

Study in live animals

John 2021

Context

Route

Amount

How often

How long

Agreement

Sources

Copying the phase 2 trial doses (reported as niche)

subcutaneous injection

0.3 to 4.5 mg per dose

once weekly

26 to 68 weeks

single source; the source carries seller links

"DIY CagriSema": cagrilintide plus semaglutide from separate products

subcutaneous injectiontwo separate products

2.4 mg per dose

once weekly

ongoing

single source; the source carries seller links

Cagrilintide

Cagrilintide at a glance

What is cagrilintide?

The history of cagrilintide

Cagrilintide structure and chemistry

What cagrilintide studies show

Weight and appetite

Blood sugar

Heart and blood vessels

Cholesterol and blood fats

Survival and serious illness

Hormones

Key cagrilintide studies

Cagrilintide clinical trials

Is cagrilintide approved?

Cagrilintide side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about cagrilintide

Related peptides

Sources

Cagrilintide

Cagrilintide at a glance

What is cagrilintide?

The history of cagrilintide

Cagrilintide structure and chemistry

What cagrilintide studies show

Weight and appetite

Blood sugar

Heart and blood vessels

Cholesterol and blood fats

Survival and serious illness

Hormones

Key cagrilintide studies

Cagrilintide clinical trials

Is cagrilintide approved?

Cagrilintide side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about cagrilintide

Related peptides

Sources